RespireRx Pharmaceuticals subsidiary ResolutionRX signs on iNGENu as CRO for dronabinol development
News release
by
RespireRx Pharmaceuticals
New York
|
March 03, 2023 11:14 AM Eastern Standard Time
RespireRX Pharmaceuticals chief financial officer Jeff Margolis joins Proactive's Natalie Stoberman with the news that subsidiary ResolutionRX has announced a services agreement with Australian contract research organization (CRO) iNGENu.
Margolis said iNGENu will act as a full-service CRO in support of ResolutionRx’s research and development program, which is developing a proprietary formulation of dronabinol for the treatment of obstructive sleep apnea and anorexia.
Contact Details
Proactive United States
+1 347-449-0879
